Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cardiff Oncology ( (CRDF) ) has provided an update.
Cardiff Oncology disclosed that on January 26, 2026 its CEO, Dr. Mark Erlander, and CFO, James Levine, stepped down as part of a strategic review, and on March 27, 2026 the company formalized their departures with separation agreements. Erlander will receive one year of his $635,000 base salary, his 2025 bonus, a pro-rated portion of his 2026 target bonus, continued healthcare for up to 12 months, extended stock option vesting until June 2026, and will remain as a consultant.
Levine will receive one year of his $490,000 base salary, his 2025 bonus, a pro-rated portion of his 2026 target bonus, continued healthcare for up to 12 months, and a 12-month post-separation exercise window for vested stock options. Both executives agreed to general release and confidentiality terms, highlighting a structured leadership transition that may influence Cardiff Oncology’s strategic direction and corporate governance stability during its review process.
The most recent analyst rating on (CRDF) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cardiff Oncology stock, see the CRDF Stock Forecast page.
Spark’s Take on CRDF Stock
According to Spark, TipRanks’ AI Analyst, CRDF is a Neutral.
The score is primarily constrained by weak financial performance (minimal revenue, large ongoing losses, and sustained cash burn with shrinking equity), reinforced by bearish technical momentum (below key moving averages and negative MACD). Offsetting factors include a low-debt balance sheet and positive program-related corporate updates that could improve prospects if regulatory/clinical milestones are achieved.
To see Spark’s full report on CRDF stock, click here.
More about Cardiff Oncology
Cardiff Oncology, Inc. is a biotechnology company focused on developing oncology therapies. The company operates in the biopharmaceutical sector, concentrating on treatments for cancer patients and targeting growth opportunities in the oncology drug development market.
Average Trading Volume: 1,091,533
Technical Sentiment Signal: Sell
Current Market Cap: $110.1M
For an in-depth examination of CRDF stock, go to TipRanks’ Overview page.